Home - The Accelerating Medicines Partnership (AMP) Heart Failure (HF) Program

The Accelerating Medicines Partnership (AMP)
Heart Failure (HF) is an innovative new project that
uses next-generation phenomics to define heart failure
subtypes and treatment targets

The Accelerating Medicines
Partnership® (AMP®) Heart
Failure (HF)

AMP-HF

Important Updates

Quick Access to Study Information

2023-2024 Reasearch Skills Trainees

The HeartShare Research Skills Program trainees for the 2022-2023 academic year have been announced. They have started their 3-month bootcamp to receive hands-on training in data management, programming, and application of machine learning and artificial intelligence approaches to clinical research in data science. They will spend the remaining 9 months in the program to complete a mentored research project related to HFpEF, using the approaches they learned in the data science bootcamp.

For more information about the program and to meet the trainees visit the Research Skills Program page.

Latest News

HeartShare Participant Newsletter Spring 2024

HeartShare Participant Newsletter Autumn 2023

2024-25 Research Skills Program Cohort

Participate in the Study

Study Sites

The AMP HF Study consists of a data translation center and 6 clinical research centers.

FAQ

If you or a family member is interested in the HeartShare study, or if you or a family member have been invited to participate, you may have questions. Review our frequently asked questions to get the answers you are looking for or contact us for more information.

What is HFpEF?

What are some reasons to participate in the study?

How long will my participation in this research last?

What will I do in this study?

I don’t have heart failure. Can I still participate?

I’m not near a study site. Can I still participate?

Study Design

The AMP HF Study is an innovative multi-center study of HFpEF, funded by NHLBI to define HFpEF subtypes and treatment targets.

HeartShare is comprised of retrospective and prospective components.

The HeartShare Retrospective study will aggregate and harmonize data from previously completed cohort studies and trials. The phenotype data will be combined with an image repository and additional omics assays.

The HeartShare Deep Phenotyping Study is composed of 2 prospective, multicenter, longitudinal components: (1) the HeartShare Registry and (2) the HeartShare Deep Phenotyping Cohort study involving up to 10,000 and 2,000 participants, respectively, enrolled from at least 6 HeartShare Clinical Centers.

Study Design

Retrospective and Prospective Data

Multiple data types will be harmonized.

Existing data sets from cohort studies and trials, including images and omics analyses, will be aggregated and harmonized to establish the retrospective data.

Details of what cohort studies and trials will be in the retrospective data will be available soon.

Prospective data will generated from the registry and deep phenotyping study cohorts. Both cohorts will have baseline and longitudinal data.

To learn more about the prospective data:

Protocol Study Procedures I/E Criteria